NASDAQ:FOLD - Amicus Therapeutics Stock Price, Price Target & More

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.08. The biopharmaceutical company earned $16.70 million during the quarter, compared to the consensus estimate of $16.78 million. Amicus Therapeutics had a negative return on equity of 60.09% and a negative net margin of 563.98%. View Amicus Therapeutics' Earnings History.

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Amicus Therapeutics.

7 equities research analysts have issued 12-month price objectives for Amicus Therapeutics' stock. Their predictions range from $15.00 to $24.00. On average, they anticipate Amicus Therapeutics' stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 22.0% from the stock's current price. View Analyst Ratings for Amicus Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Amicus Therapeutics saw a decline in short interest during the month of June. As of June 29th, there was short interest totalling 26,797,082 shares, a decline of 8.6% from the June 15th total of 29,318,771 shares. Based on an average trading volume of 2,274,682 shares, the days-to-cover ratio is presently 11.8 days. Currently, 14.6% of the shares of the stock are sold short. View Amicus Therapeutics' Current Options Chain.

Some companies that are related to Amicus Therapeutics include Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), FibroGen (FGEN), United Therapeutics (UTHR) and Loxo Oncology (LOXO).

News headlines about FOLD stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amicus Therapeutics earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.05 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Amicus Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Berson & Corrado Investment Advisors LLC (0.02%), Verde Servicos Internacionais S.A. (0.02%), Xact Kapitalforvaltning AB (0.02%), Amalgamated Bank (0.02%), Fox Run Management L.L.C. (0.01%) and Fortaleza Asset Management Inc. (0.00%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

FOLD stock was sold by a variety of institutional investors in the last quarter, including Verde Servicos Internacionais S.A. and Fortaleza Asset Management Inc.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.

FOLD stock was acquired by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Exane Derivatives, Berson & Corrado Investment Advisors LLC, Amalgamated Bank and Xact Kapitalforvaltning AB. Company insiders that have bought Amicus Therapeutics stock in the last two years include John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FOLD stock can currently be purchased for approximately $15.98.

Amicus Therapeutics has a market capitalization of $2.97 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]